Inhibitory kinaz 4/6 zależnych od cyklin — podobieństwa i różnice

Treatment of hormone dependent HER2 negative breast cancer evolves depending on the continuous understanding of the mechanisms regulating the development of hormone resistance in cancer cells. Currently, the therapeutic options in advanced ER-positive HER-2 negative breast cancer are quite broad and allow long-term survival with a good quality of life. Hormone therapy in monotherapy was the standard so far. The breakthrough discovery was cyclin-dependent kinase inhibitors, which entered standard therapy and changed the clinical practice in the first line of treatment of metastatic breast cancer. After positive results of studies in terms of overall survival and progression-free time in metastatic breast cancer, studies on the effectiveness of inhibitors in different types of breast cancer and in neo- or adjuvant treatment in configurations with the known treatment were initiated. This paper discusses the clinical trials that have contributed to the registration of CDK 4/6 inhibitors and those that are currently underway. The individual inhibitors were also compared in terms of treatment efficacy results and possible treatment toxicity. The safety profile of the treatment of a special group of patients, such as the elderly, was also discussed.